SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

Search

Pharma Mar SA

Închisă

84.6 -7.74

Rezumat

Modificarea prețului

24h

Curent

Minim

83

Maxim

85.05

Indicatori cheie

By Trading Economics

Venit

-13M

-3.9M

Vânzări

-9.5M

39M

P/E

Medie Sector

78.186

51.198

EPS

-0.22

Randament dividend

0.91

Marjă de profit

-10.047

Angajați

500

EBITDA

-16M

-1.1M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+18.61% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.91%

2.40%

Următoarele câștiguri

29 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

141M

1.5B

Deschiderea anterioară

92.34

Închiderea anterioară

84.6

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Pharma Mar SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

6 iun. 2025, 14:31 UTC

Câștiguri

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 iun. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 iun. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 iun. 2025, 20:33 UTC

Câștiguri

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 iun. 2025, 19:36 UTC

Market Talk

Oil Futures Post Solid Weekly Gains -- Market Talk

6 iun. 2025, 19:28 UTC

Market Talk

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 iun. 2025, 18:46 UTC

Market Talk

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 iun. 2025, 18:02 UTC

Market Talk

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 iun. 2025, 16:35 UTC

Câștiguri

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 iun. 2025, 16:34 UTC

Câștiguri

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 iun. 2025, 16:21 UTC

Market Talk

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 iun. 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 iun. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 iun. 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

6 iun. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 iun. 2025, 16:07 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

6 iun. 2025, 16:07 UTC

Market Talk

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 iun. 2025, 15:53 UTC

Market Talk

Mexican Inflation Seen Rising in May -- Market Talk

6 iun. 2025, 15:36 UTC

Market Talk

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 iun. 2025, 15:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 iun. 2025, 15:33 UTC

Market Talk

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 iun. 2025, 15:16 UTC

Market Talk

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 iun. 2025, 15:05 UTC

Market Talk

Silver at its Highest In Nearly 15 Years -- Market Talk

6 iun. 2025, 14:35 UTC

Market Talk

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 iun. 2025, 14:28 UTC

Market Talk

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 iun. 2025, 14:28 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 iun. 2025, 14:28 UTC

Market Talk

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 iun. 2025, 14:15 UTC

Market Talk

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 iun. 2025, 14:12 UTC

Câștiguri

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 iun. 2025, 14:09 UTC

Câștiguri

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Comparație

Modificare preț

Pharma Mar SA Așteptări

Obiectiv de preț

By TipRanks

18.61% sus

Prognoză pe 12 luni

Medie 108.999 EUR  18.61%

Maxim 110 EUR

Minim 108 EUR

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPharma Mar SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

2

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

72.75 / 74.3Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.